<DOC>
	<DOCNO>NCT01008904</DOCNO>
	<brief_summary>RATIONALE : Magnesium oxide may help relieve hot flash woman cancer . PURPOSE : This phase II trial study well magnesium oxide work treat hot flash menopausal woman cancer .</brief_summary>
	<brief_title>Magnesium Oxide Treating Hot Flashes Menopausal Women With Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine magnesium oxide supplement decrease frequency severity hot flash 50 % menopausal woman cancer . Secondary - To evaluate effect magnesium oxide overall quality life . - To evaluate toxicity magnesium oxide administer commonly use supplement dos . OUTLINE : Patients receive oral magnesium oxide daily week 2-5 . Patients whose hot flash satisfactorily control 2 week treatment may receive magnesium oxide twice daily week 4 5 . Patients complete daily hot flash diary 5 week begin 1 week treatment . Patients also complete quality-of-life , symptom , self-assessment questionnaire baseline , weekly treatment , completion treatment . After completion study treatment , patient follow least 30 day .</detailed_description>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Magnesium Oxide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Meets 1 follow criterion : History breast cancer ( currently without malignant disease ) No history breast cancer wish avoid estrogen due perceive increased risk breast cancer Must bothersome hot flash ( define occurrence ≥ 14 time per week sufficient severity make patient desire therapeutic intervention ) ≥ 1 month study entry Has undergone treatment cancer ( patient breast cancer survivor eligible ) PATIENT CHARACTERISTICS : Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Creatinine clearance ≥ 30 mL/min No hypersensitivity magnesium oxide No medical condition ( ) , opinion investigator/subinvestigator , may compromise objective study PRIOR CONCURRENT THERAPY : See Disease Characteristics More 4 week since prior concurrent antineoplastic chemotherapy , androgen , estrogen , progestational agent , gabapentin More 28 day since prior concurrent investigational drug Concurrent tamoxifen , raloxifene , aromatase inhibitor allow provided patient constant dose &gt; 4 week AND expect stop medication study period</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>cancer survivor</keyword>
	<keyword>hot flash</keyword>
	<keyword>breast cancer</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>